Staidson (Beijing) BioPharmaceuticals Co., Ltd. primarily engages in the research, development, production, and marketing of therapeutic and biological drugs in China. The company offers protein drugs, including therapeutic monoclonal antibody drugs; chemical drugs; and drugs for urinary, intestinal, infectious, autoimmune, nervous system, and other diseases. It also provides treatments for respiratory and critical care illnesses, and neurological disorders. Its product portfolio includes Mouse Nerve Growth factor for injection, Compound Polyethylene Glycol Electrolyte Powder (IV), Aspirin enteric-coated tablets, Compound polyethylene glycol (3350) electrolyte oral solution, Compound polyethylene glycol (3350) electrolyte vitamin C powder. Staidson (Beijing) BioPharmaceuticals Co., Ltd. was founded in 2002 and is based in Beijing, China.
Research context
Staidson (Beijing) BioPharmaceuticals Co., Ltd appears in PyInvesting’s Shenzhen Stock catalogue. The price history above describes this recorded instrument; it does not by itself identify a company’s business or establish a continuous investment return.
- Currency
- CNY
- Sector
- Healthcare
- Industry
- Biotechnology
These are the latest stored catalogue classifications, not a historical classification snapshot. An issuer description, classification effective date or currency may be unavailable. Check the issuer’s own disclosures and the observation dates before using these fields for research.
Review backtest assumptions and evidence before treating a chart or stored history as a research result.
5 years, 6 months ago
Staidson (Beijing) BioPharmaceuticals Co., Ltd is currently in a long term uptrend where the price is trading 14.4% above its 200 day moving average.
From a valuation standpoint, the stock is 12.8% cheaper than other stocks from the Healthcare sector with a price to sales ratio of 8.4.
Staidson (Beijing) BioPharmaceuticals Co., Ltd's total revenue sank by 27.4% to $130M since the same quarter in the previous year.
Its net income has dropped by 530.1% to $-23M since the same quarter in the previous year.
Finally, its free cash flow fell by 421.9% to $-36M since the same quarter in the previous year.
Based on the above factors, Staidson (Beijing) BioPharmaceuticals Co., Ltd gets an overall score of 2/5.